CERK and neoplasm: Accordingly, CERK overexpression showed to be a biomarker for chemotherapeutic response in TNBC and higher than two-fold change in CERK (from tumor)/CERK (from normal counterpart) ratio was significantly linked to chemoresistance to doxorubicin and paclitaxel (OR = 2.66, 95% CI 1.18–7.34), p = 0.04.